2026-07-21T14:20:14Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/186862024-09-21T20:01:27Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927col_20.500.12105_16960
Repisalud
author
Pérez-Belmonte, Luis M
author
Sanz-Cánovas, Jaime
author
García de Lucas, María D
author
Ricci, Michele
author
Avilés-Bueno, Beatriz
author
Cobos-Palacios, Lidia
author
Pérez-Velasco, Miguel A
author
López-Sampalo, Almudena
author
Bernal-López, M Rosa
author
Jansen-Chaparro, Sergio
author
Miramontes-González, José P
author
Gómez-Huelgas, Ricardo
2024-02-27T15:08:48Z
2024-02-27T15:08:48Z
2022-06-24
10.3389/fendo.2022.851035
1664-2392
Frontiers in endocrinology
http://hdl.handle.net/10668/20560
35813629
http://hdl.handle.net/20.500.12105/18686
The impact of glucagon-like peptide-1 receptor agonists on patients with heart failure has not been fully described. Our main objective was to evaluate the safety and clinical and glycemic efficacy of once-weekly semaglutide in obese patients with type 2 diabetes and heart failure. In this observational, retrospective, real-world study, we enrolled outpatients with type 2 diabetes, obesity, and heart failure who started semaglutide and were followed-up on at 3, 6, and 12 months. A total of 136 patients were included. From baseline to 12 months, there was a significant improvement on the Kansas City Cardiomyopathy Questionnaire total symptom score (59.0 ± 24.1 vs 79.9 ± 28.4 points, p In obese patients with type 2 diabetes and heart failure, the use of once-weekly semaglutide was safe and clinically efficacious, improving health and functional status. Nevertheless, more strong evidence on glucagon-like peptide-1 receptor agonists in heart failure is required.
eng
health status
heart failure
obesity
semaglutide
type 2 diabetes
Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice.
research article